Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia

Thrombosis and Haemostasis

Volumn 90, Issue 6, 2003, Pages 1054-1060

  Derhaschnig, Ulla ^a   Pachinger, Christine ^a   Schweeger Exeli, Ingrid ^a   Marsik, Claudia ^a   Jilma, Bernd ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Coagulation activation; Endotoxemia; Eptifibatide; Randomized controlled trial; Tirofiban

Indexed keywords

BIOCHEMICAL MARKER; D DIMER; ENDOTOXIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; INTERLEUKIN 6; MESSENGER RNA; PLACEBO; PLASMIN ANTIPLASMIN COMPLEX; PROTHROMBIN; PROTHROMBIN FRAGMENT 1 + 2; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TIROFIBAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; NEUTROPHIL; NORMAL HUMAN; PARALLEL DESIGN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOLUNTEER;

EID: 0348163666     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-04-0233     Document Type: Article

References (47)

1. Vincent JL, Yagushi A, Pradier O. Platelet function in sepsis. Crit Care Med 2002; 30: S313-S317.
2. Hoffman M, Monroe DM, III. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
3. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996; 98: 863-74.
4. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-401.
5. Fujimoto T, Hawiger J. Adenosine diphosphate induces binding of von Willebrand factor to human platelets. Nature 1982; 297: 154-6.
6. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem 1979; 254: 5357-63.
7. Plow EF, Ginsberg MH. Specific and saturable binding of plasma fibronectin to thrombin-stimulated human platelets. J Biol Chem 1981; 256: 9477-82.
8. Ruggeri ZM, Bader R, De Marco L. Glanzmann thrombasthenia: Deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci U S A 1982; 79: 6038-41.
9. Byzova TV, Plow EF. Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation. J Biol Chem 1997; 272: 27183-8.
10. Plow EF, Cierniewski CS, Xiao Z, et al. Alpha IIbbeta3 and its antagonism at the new millennium. Thromb Haemost 2001; 86: 34-40.
11. Pu Q, Wiel E, Corseaux D, et al. Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endothelium in Escherichia coli endotoxin-induced shock. Crit Care Med 2001; 29: 1181-8.
12. Merlini PA, Repetto A, Lombardi A, et al. Effect of Abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy. Circulation 2002; 105: 928-32.
13. Ambrose JA, Hawkey M, Badimon JJ, et al. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol 2000; 86: 150-2.
14. Ambrose JA, Doss R, Geagea JM, et al. Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention. Am J Cardiol 2001; 87: 1231-3.
15. Kleiman NS. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. Am Heart J 1999; 138: 263-75.
16. Pernerstorfer T, Hollenstein U, Hansen J, et al. Heparin blunts endotoxin-induced coagulation activation. Circulation 1999; 100: 2485-90.
17. Franco RF, De Jonge E, Dekkers PE, et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: Relationship with activation of coagulation. Blood 2000; 96: 554-9.
18. Hollenstein U, Homoncik M, Knobl P, et al. Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans. Clin Pharmacol Ther 2002; 71: 368-74.
19. Suffredini AF, Hochstein HD, McMahon FG. Dose-related inflammatory effects of intravenous endotoxin in humans: Evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis 1999; 179.
20. Jilma B, Blann A, Pernerstorfer T, et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 1999; 159: 857-63.
21. Pernerstorfer T, Stohlawetz P, Hollenstein U, et al. Endotoxin-induced activation of the coagulation cascade in humans: Effect of acetylsalicylic acid and acetaminophen. Arterioscler Thromb Vasc Biol 1999; 19: 2517-23.
22. Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J 1999; 138: 317-26.
23. Sharma S, Bhambi B, Nyitray W, et al. Delayed profound thrombocytopenia presenting 7 days after use of abciximab (ReoPro). J Cardiovasc Pharmacol Ther 2002; 7: 21-24.
24. Derhaschnig U, Laggner AN, Roggla M, et al. Evaluation of coagulation markers for early diagnosis of acute coronary syndromes in the emergency room. Clin Chem 2002; 48: 1924-30.
25. Jilma B, Marsik C, Mayr F, et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 2002; 72: 403-10.
26. Rainen L, Oelmueller U, Jurgensen S, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem 2002; 48: 1883-90.
27. Derhaschnig U, Reiter R, Knobl P, et al. Recombinant human activated protein C (rhAPC, drotrecogin alfa activated) has minimal effect on markers of coagulation, fibrinolysis and inflammation in acute human endotoxemia. Blood 2003; 102: 2108-14.
28. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-8.
29. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986; 39: 489-90.
30. Pernerstorfer T, Hollenstein U, Hansen JB, et al. Lepirudin blunts endotoxin-induced coagulation activation. Blood 2000; 95: 1729-34.
31. Fay WP, Parker AC, Ansari MN, et al. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 1999; 93: 1825-30.
32. Parker CJ, Stone OL, White VF, et al. Vitronectin (S protein) is associated with platelets. Br J Haematol 1989; 71: 245-52.
33. Coller BS. Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: With a review of platelet-leukocyte interactions. Thromb Haemost 1999; 82: 326-36.
34. Butenas S, Cawthern KM, Van't Veer C, et al. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001; 97: 2314-22.
35. Thomas S, Metcalfe P, Goodall AH, et al. Monoclonal antibodies against platelet membrane glycoproteins IIb/IIIa and Ibalpha inhibit platelet dependent thrombin generation by different mechanisms. Thromb Haemost 2000; 84(1): 98-103.
36. Li Y, Spencer FA, Ball S, et al. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes. J Thromb Thrombolysis 2000; 10(1): 69-76.
37. Kageyama S, Yamamoto H, Nakazawa H, et al. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol 2002; 22: 187-92.
38. Taylor FB, Coller BS, Chang AC, et al. 7E3 F(ab′)2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli. Blood 1997; 89: 4078-84.
39. Rao AK, Sun L, Hiramatsu Y, Gorman JH, III, Edmunds LH, Jr. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons. Thromb Haemost 1999; 82: 140-44.
40. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966; 196: 436-40.
41. Dangas G, Badimon JJ, Coller BS, et al. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: Implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol 1998; 18: 1342-9.
42. Van Der Poll T, Calvano SE, Kumar A, et al. Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood 1995; 86: 2754-9.
43. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104: 163-7.
44. Fijnheer R, Frijns CJ, Korteweg J, et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 77: 1081-5.
45. Jilma-Stohlawetz P, Folman CC, Dem Borne AE, et al. Effects of anticoagulation on thrombopoietin release during endotoxemia. J Lab Clin Med 2001; 137(1): 64-9.
46. Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-7.
47. Stohlawetz P, Folman CC, Dem Borne AE, et al. Effects of endotoxemia on thrombopoiesis in men. Thromb Haemost 1999; 81: 613-7.